Tessa Therap 
Welcome,         Profile    Billing    Logout  
 4 Products   0 Diseases  4 Products   8 Trials   35 News 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TT11 / Tessa Therap, UNC Lineberger Comprehensive Cancer Center, Baylor Scott & White Research Institute
CHARIOT, NCT04268706: Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting
2
97
US
CD30.CAR-T, Fludarabine, Fludara, Bendamustine, Bendeka
Tessa Therapeutics
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
05/25
03/37
NCT05634785: CD30 CAR for CD30+ NSGCT

Recruiting
2
18
US
ATLCAR.CD30 Cells, CAR.CD30 T cells, Cyclophosphamid, Cytoxan, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center, University Cancer Research Fund at Lineberger Comprehensive Cancer Center
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor
12/26
12/26
NCT04083495: CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Recruiting
2
20
US
ATLCAR.CD30 T cells, Bendamustine, Bendeka, Fludarabine, Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Peripheral T Cell Lymphoma
02/28
08/38
NCT02690545: Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Recruiting
1/2
40
US
ATLCAR.CD30 cells, CAR.CD30 T cells
UNC Lineberger Comprehensive Cancer Center
Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
09/27
08/38
NCT06090864: ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

Recruiting
1/2
31
US
Chemotherapy, Cell infusion
UNC Lineberger Comprehensive Cancer Center
Hodgkin Lymphoma, Relapse, Refractory
07/26
07/31
ACTION, NCT05352828: Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

Active, not recruiting
1b
15
US
Nivolumab, Opdivo, Autologous CD30.CAR-T, CD30-directed CAR-T cells, Fludarabine, Fludara, Bendamustine, Bendeka, Treanda
Tessa Therapeutics, Bristol-Myers Squibb
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
12/25
12/37
NCT02663297: Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Active, not recruiting
1
18
US
ATLCAR.CD30 cells, CAR.CD30 T cells
UNC Lineberger Comprehensive Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
01/21
01/37
CERTAIN, NCT04526834: Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Active, not recruiting
1
21
US
CD30.CAR-T, CD30-directed genetically modified autologous T cells
Tessa Therapeutics
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
11/22
03/36
NCT02917083: CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Recruiting
1
60
US
CAR T Cells, CD30.CAR T Cells
Baylor College of Medicine, The Methodist Hospital Research Institute
Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
04/26
02/40
LCCC 1606-ATL, NCT03602157: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Recruiting
1
59
US
ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine, Fludarabine
UNC Lineberger Comprehensive Cancer Center, University Cancer Research Fund at Lineberger Comprehensive Cancer Center, Stand Up To Cancer
Lymphoma, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Cutaneous Lymphoma, Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis, Cutaneous T Cell Lymphoma, Gray Zone Lymphoma
09/26
09/41
NCT03914885: Compassionate Use Re-Infusion of ATLCAR.CD30

No Longer Available
N/A
US
ATLCAR.CD30, CD30 CAR T cells, Bendamustine, Bendeka, Treanda, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center
Hodgkin Lymphoma, Adult
 
 
TT16 / Tessa Therap
VISTA, NCT03740256: Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

Recruiting
1
45
US
CAdVEC, HER2-specificCAR- T
Baylor College of Medicine, The Methodist Hospital Research Institute
Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Solid Tumor
12/24
12/38
TT12 / Tessa Therap
HESTIA, NCT02379520: HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers,

Active, not recruiting
1
32
US
HPV Specific T Cells, HPVSTs, Cytoxan, cyclophosphamide, Fludarabine, Fludara, Nivolumab, Opdivo
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute
Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma, Human Papillomavirus Positive Anal Carcinoma, Human Papillomavirus Positive Vulvar Carcinoma, Human Papillomavirus Positive Penile Carcinoma
10/24
10/33
TT11X / Tessa Therap
CABAL2, NCT06176690: Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Not yet recruiting
1
90
US
C7R.CD30.CAR-EBVST cells, Allogeneic CR7.CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine
CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive, Peripheral T-cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-negative, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
07/28
06/43
NCT04288726: Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Recruiting
1
18
US
CD30.CAR-EBVST cells, Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes
Baylor College of Medicine, The Methodist Hospital Research Institute
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
06/25
06/37
NCT04952584: Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

Withdrawn
1
18
US
CD30.CAR-EBVST cells, Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes
Baylor College of Medicine, The Methodist Hospital Research Institute
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
06/25
06/40
TT20X / Tessa Therap
No trials found

Download Options